Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.

@article{Faderl2010AlemtuzumabBC,
  title={Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.},
  author={Stefan J Faderl and Alessandra Ferrajoli and William G Wierda and Susan O'brien and Susan K. Lerner and Michael J Keating},
  journal={Cancer},
  year={2010},
  volume={116 10},
  pages={
          2360-5
        }
}
BACKGROUND Monoclonal antibodies may be used more effectively in combination. A previous study of intravenous (iv) bolus alemtuzumab plus rituximab in patients with chronic lymphocytic leukemia (CLL) recurrence produced a response rate of 54% after a 4-week treatment period. METHODS To optimize dose, schedule, and route of alemtuzumab, a study was designed exploring continuous intravenous infusion (civ) followed by subcutaneous (sc) alemtuzumab together with weekly iv rituximab in patients… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017

[Chronic lymphocytic leukemia].

  • Deutsche medizinische Wochenschrift
  • 2013